Clinical trials: Anti-CD20 Therapy
B-Cell Non-Hodgkin Lymphoma (B-NHL)
A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma
This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on patients with previously treated aggressive B-cell non-Hodgkin lymphoma whose cancer has stopped responding to…
- Trial name
- OLYMPIA-4 (NCT06230224)
- Testing
- Odronextamab, Ifosfamide, Carboplatin
- Where
- 81 sites in Argentina, Australia and 12 more
- Volunteers
- 216 people
- Sponsor
- Regeneron Pharmaceuticals
Pemphigus
Treatment of Pemphigus Patients With Rituximab 1000mgX2 and Assessment of Immune Status Via Cylex
The purpose of this study is to determine whether Rituximab, in the same doses as used in rheumatoid arthritis patients, will benefit pemphigus patients.
- Trial name
- NCT01338103
- Testing
- Rituximab
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- Rabin Medical Center
Graft vs Host Disease
Combination of Alemtuzumab and Rituximab at Low-doses in Refractory Chronic Graft-Versus-Host Disease
The purpose of this study is to determine whether low-doses alemtuzumab and rituximab combination are effective in the treatment of chronic graft-versus-host disease (GVHD) after first-line therapy failure.
- Trial name
- LowAR (NCT01042509)
- Testing
- Alemtuzumab and rituximab
- Where
- Mexico
- Volunteers
- 15 people
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
Sjogren's Disease
Tolerance and Efficacy of Rituximab in Sjogren's Disease
CLINICAL PHASE II INDICATION Sjogren's syndrome RATIONALE Sjögren's syndrome (SS) is an autoimmune disorder affecting 0.2% to 3% of the general population.
- Trial name
- TEARS (NCT00740948)
- Testing
- Rituximab (mabthera) Injection
- Where
- 14 sites in France
- Volunteers
- 122 people
- Sponsor
- University Hospital, Brest
Chronic Fatigue Syndrome, Myalgic Encephalomyelitis
B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Very Severe Chronic Fatigue Syndrome
Based on pilot patient observations, and experience from the prior study KTS-1-2008, the investigators anticipate that severely affected chronic fatigue syndrome patients may benefit from B-cell depletion therapy using Rituximab…
- Trial name
- NCT01156922
- Testing
- Rituximab
- Where
- Norway
- Volunteers
- 8 people
- Sponsor
- Haukeland University Hospital
Low-Grade or Follicular B-Cell Non-Hodgkin's Lymphoma
Treatment of Relapsed Low-Grade or Follicular Lymphoma With Rituximab (Also Known as Rituxan, IDEC-C2B8, IDEC-102)
Rituximab is an antibody made in a laboratory. It binds to lymphoma cells and kills them. Treatment of recurrent B-cell lymphoma with rituximab may delay or prevent relapses.
- Trial name
- NCT00168740
- Testing
- rituximab
- Where
- 31 sites in United States, Canada
- Volunteers
- 150 people
- Sponsor
- Biogen
Relapsed and/or Refractory B-cell Lymphoma
Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma
The goal of this clinical study is to learn more about the safety and effectiveness of the study drugs, KITE-363 and KITE-753, in participants with relapsed and/or refractory B-cell lymphoma.
- Trial name
- PALISADES-1 (NCT04989803)
- Testing
- Cyclophosphamide, Fludarabine, KITE-363
- Where
- 36 sites in United States, Australia and 4 more
- Volunteers
- 247 people
- Sponsor
- Kite, A Gilead Company
Lymphoma, Non-Hodgkin
GOAL: GA101 Plus Pixantrone for Relapsed Aggressive Lymphoma
The purpose of this study is to evaluate the overall response rate of Obinutuzumab (GA101) in combination with Pixantrone in patients with relapsed aggressive B-cell lymphoma.
- Trial name
- NCT02499003
- Testing
- Obinutuzumab and Pixantrone
- Where
- Germany
- Volunteers
- 70 people
- Sponsor
- Johannes Gutenberg University Mainz
CLL/SLL
REtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL)
Fixed-duration regimens containing combinations of venetoclax with CD20 targeting agents are expected to soon become standard practice in first-line patients with chronic lymfocytic leukemia (CLL).
- Trial name
- NCT04523428
- Testing
- Venetoclax/Acalabrutinib
- Where
- 18 sites in Belgium, Denmark and 1 more
- Volunteers
- 60 people
- Sponsor
- Stichting Hemato-Oncologie voor Volwassenen Nederland
Systemic Lupus Erythematosus (SLE), ANCA Associated Vasculitis (AAV)
IMPT-514 in Systemic Lupus Erythematosus, Anca-associated Vasculitis, and Idiopathic Inflammatory Myopathy
This is an exploratory trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of a single dose of IMPT-514, an autologous, anti-CD19/CD20 CAR T therapy, administered as an intravenous (IV)…
- Conditions
- Systemic Lupus Erythematosus (SLE), ANCA Associated Vasculitis (AAV), Idiopathic Inflammatory Myopathy (IIM)
- Trial name
- NCT06462144
- Testing
- IMPT-514 CART Cell Injection
- Where
- 3 sites in China
- Volunteers
- 3 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Pulmonary Alveolar Proteinosis (PAP), Severe Mucocutaneous Candidiasis
Rituximab for Anti-cytokine Autoantibody-Associated Diseases
Background: Healthy people have white blood cells that protect them against bacteria, viruses, and fungi. However, some people have diseases which cause the body to make white blood cells that do not work properly.
- Trial name
- NCT01842386
- Testing
- Rituximab
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Diffuse Large B-Cell Lymphoma
Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma
The purpose of the study is to examine efficacy and safety of epcoritamab with and without lenalidomide in newly diagnosed elderly patients with Diffuse Large B-Cell Lymphoma (DLBCL) who cannot tolerate anthracycline therapy.
- Trial name
- EPCORE DLBCL-3 (NCT05660967)
- Testing
- Epcoritamab, Lenalidomide
- Where
- 74 sites in United States, Austria and 10 more
- Volunteers
- 111 people
- Sponsor
- Genmab
Diffuse, Large B-Cell, Lymphoma
A Study Comparing the Efficacy and Safety Between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients
The purpose of this study is to comparing the Efficacy and Safety between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients.
- Trial name
- NCT02867566
- Testing
- IBI301 plus CHOP, Rituximab plus CHOP
- Where
- China
- Volunteers
- 420 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Refractory Chronic Lymphocytic Leukemia
Lower But More Frequent Dose Rituximab to Treat Chronic Lymphocytic Leukemia
This study will test the safety and effectiveness of using lower-dose rituximab given more frequently for treating chronic lymphocytic leukemia (CLL).
- Trial name
- NCT00366418
- Testing
- Rituximab
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Purpura, Thrombocytopenic, Idiopathic, Autoimmune Thrombocytopenic Purpura
Study of Veltuzumab (hA20) at Different Doses in Patients With ITP
This trial will study different dose levels of hA20 (IMMU-106) to see if they are safe and effective for treating ITP.
- Conditions
- Purpura, Thrombocytopenic, Idiopathic, Autoimmune Thrombocytopenic Purpura, Purpura, Thrombocytopenic, Autoimmune
- Trial name
- NCT00547066
- Testing
- veltuzumab
- Where
- 8 sites in United States
- Volunteers
- 48 people
- Sponsor
- Gilead Sciences
Membranous Nephropathy
MOR202 for Refractory MN
Membranous nephropathy (MN) - the leading cause of nephrotic syndrome (NS) in adults - is an immune-mediated disease that results from the deposition of immunoglobulins and complement components onto the sub-epithelial layer of…
- Trial name
- MONET (NCT04893096)
- Testing
- MOR202
- Where
- 2 sites in Italy
- Volunteers
- 10 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Lymphoma
Rituximab and Dexamethasone in Treating Patients With Recurrent or Refractory Indolent Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00003663
- Testing
- rituximab, dexamethasone
- Where
- 3 sites in United States
- Sponsor
- Hoag Memorial Hospital Presbyterian
Non-Hodgkin's Lymphoma
A Study of MabThera/Rituxan (Rituximab) in Patients With Relapsed Centroblastic Centrocytic Non-Hodgkin's Lymphoma
This study will evaluate the efficacy and safety of MabThera/Rituxan in patients with relapsed low-grade centroblastic centrocytic non-Hodgkin's lymphoma.
- Trial name
- NCT01998893
- Testing
- rituximab [MabThera/Rituxan]
- Where
- 11 sites in Germany
- Volunteers
- 38 people
- Sponsor
- Hoffmann-La Roche
Lymphoma
Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver…
- Trial name
- NCT00004179
- Testing
- rituximab, CHOP regimen, cyclophosphamide
- Where
- 261 sites in Australia, Belgium and 16 more
- Volunteers
- 475 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Multiple Sclerosis, Primary Progressive Multiple Sclerosis
C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Progressive Multiple Sclerosis Refractory to Standard Therapy
This is a global, multicenter, Phase 1b/2 study evaluating the safety and efficacy of C-CAR168, an autologous anti-CD20/BCMA chimeric antigen receptor T-cell therapy, in participants with progressive multiple sclerosis refractory…
- Conditions
- Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Secondary Progress Multiple Sclerosis (SPMS), Primary Progressive Multiple Sclerosis (PPMS)
- Trial name
- NCT07825389
- Testing
- C-CAR168
- Where
- 2 sites in United States
- Volunteers
- 119 people
- Sponsor
- AbelZeta Inc.